Cellular and Tissue Selectivity of AAV Serotypes for Gene Delivery to Chondrocytes and Cartilage by 박광환 et al.





International Journal of Medical Sciences 
2021; 18(15): 3353-3360. doi: 10.7150/ijms.56760 
Research Paper 
Cellular and Tissue Selectivity of AAV Serotypes for 
Gene Delivery to Chondrocytes and Cartilage 
Dong Suk Yoon1#, Kyoung-Mi Lee1,2#, Sehee Cho1,3#, Eun Ae Ko1, Jihyun Kim1, Sujin Jung1, Jae-Hyuck 
Shim4,5,6, Guangping Gao5,6,7,8, Kwang Hwan Park1, Jin Woo Lee1,2,3 
1. Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul 03722, South Korea 
2. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, South Korea 
3. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, South Korea 
4. Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA 01605, USA 
5. Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA 01605, USA 
6. Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA 
7. Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01605, USA 
8. Viral Vector Core, University of Massachusetts Medical School, Worcester, MA 01605, USA 
# DSY, K-ML, and SC contributed equally to this work and are co-first authors to this article.  
 Corresponding author: Professor Jin Woo Lee, Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul 03722, South Korea; 
ljwos@yuhs.ac (Tel: +82 2 2228 2190) and Professor Kwang Hwan Park, Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul 03722, 
South Korea; khpark@yuhs.ac (Tel: +82 2 2228 2185) 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2020.12.04; Accepted: 2021.07.20; Published: 2021.07.25 
Abstract 
Background: Despite several studies on the effect of adeno-associated virus (AAV)-based therapeutics 
on osteoarthritis (OA), information on the transduction efficiency and applicable profiles of different 
AAV serotypes to chondrocytes in hard cartilage tissue is still limited. Moreover, the recent discovery of 
additional AAV serotypes makes it necessary to screen for more suitable AAV serotypes for specific 
tissues. Here, we compared the transduction efficiencies of 14 conventional AAV serotypes in human 
chondrocytes, mouse OA models, and human cartilage explants obtained from OA patients. 
Methods: To compare the transduction efficiency of individual AAV serotypes, green fluorescent 
protein (GFP) expression was detected by fluorescence microscopy or western blotting. Likewise, to 
compare the transduction efficiencies of individual AAV serotypes in cartilage tissues, GFP expression 
was determined using fluorescence microscopy or immunohistochemistry, and GFP-positive cells were 
counted. 
Results: Only AAV2, 5, 6, and 6.2 exhibited substantial transduction efficiencies in both normal and OA 
chondrocytes. All AAV serotypes except AAV6 and rh43 could effectively transduce human bone 
marrow mesenchymal stem cells. In human and mouse OA cartilage tissues, AAV2, AAV5, AAV6.2, 
AAV8, and AAV rh39 showed excellent tissue specificity based on transduction efficiency. These results 
indicate the differences in transduction efficiencies of AAV serotypes between cellular and tissue models. 
Conclusions: Our findings indicate that AAV2 and AAV6.2 may be the best choices for AAV-mediated 
gene delivery into intra-articular cartilage tissue. These AAV vectors hold the potential to be of use in 
clinical applications to prevent OA progression if appropriate therapeutic genes are inserted into the 
vector. 
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Introduction 
Gene delivery to cartilage tissue by intra- 
articular administration can serve as an attractive 
strategy for treating osteoarthritis (OA), except that 
vector access to hard cartilage tissue may be a limiting 
factor[1]. The ideal vector for introducing genes into 
hard cartilage tissue would enable sustained and 
stable gene expression in the tissue. Moreover, the 








procedures without triggering serious 
vector-mediated inflammatory responses in the 
patients. In recent years, the use of adeno-associated 
virus (AAV) vectors has been considered the most 
promising strategy for delivering therapeutic 
genes.[2] Not only can recombinant AAV be 
transduced into various tissues, but these vectors can 
also maintain AAV-induced gene expression for a 
long time without triggering an inflammatory 
response in vivo.[3] To date, many studies have 
reported that AAV serotype capsids exhibit tissue 
specificities and different transduction efficiencies.[4] 
As systemic and rational administration of AAV 
vectors derived from alternative serotypes is a 
powerful strategy for the successful delivery of 
therapeutic genes to target tissues, it is vital to 
determine an appropriate AAV serotype capsid that 
can be used for efficient transgene delivery. Several 
studies regarding the use of gene therapy for cartilage 
regeneration have shown promising results,[5-7] but 
these studies used AAVs belonging to different 
serotypes. Potential differences between AAV 
serotypes may exist in experimental models of cells 
and tissues involving OA treatment or regeneration of 
damaged cartilage and should therefore be confirmed 
experimentally using a variety of in vitro and in vivo 
models, (human and mouse). It is also important to 
identify which cartilaginous cells and tissues are 
infected by AAVs after intra-articular injection and 
then use this information to develop ideal therapeutic 
strategies for intra-articular diseases such as OA.[5] 
We aimed to determine the most efficient AAV 
serotype for the gene therapy of intra-articular 
diseases. We hypothesized that the transduction 
efficiency of individual AAVs in chondrocytes and 
cartilage tissues might differ in a serotype-dependent 
manner. To test this hypothesis, we used 14 
conventional AAV vectors corresponding to different 
serotypes to identify the serotypes that can be 
efficiently delivered to chondrocytes within cartilage 
tissue. Our experiments revealed the differences in 
AAV serotype transduction efficiencies between 
chondrocytes and cartilage tissue. Our results 
revealed that AAV2 and AAV6.2 exhibited the highest 
transduction efficiencies, suggesting their use in 
AAV-mediated gene delivery into chondrocytes in 
vitro and in vivo. Furthermore, the corresponding 
vectors can be considered to represent optimal vector 
systems for clinical application in patients with 
intra-articular diseases, such as OA. 
Materials and Methods 
Cell culture 
Human articular cartilage tissues were obtained 
from the knee joints of patients with approval from 
the institutional review board (IRB; 2019-1374-002) of 
the Yonsei University College of Medicine. Cartilage 
tissue was divided into undamaged and damaged 
parts, and chondrocytes were isolated from each 
tissue by incubating the tissues with 0.1% type II 
collagenase (Thermo Fisher Scientific, Rockford, IL, 
USA). Cells isolated from undamaged cartilage 
tissues were designated as normal chondrocytes, and 
the cells isolated from damaged cartilage tissues were 
considered as osteoarthritic (OA) chondrocytes. 
Chondrocytes were cultured in high-glucose DMEM 
(DMEM-HG; Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (FBS; 
Gibco, Grand Island NY, USA) and 1% antibiotic–
antimycotic solution (Invitrogen) at 37°C and 5% CO2. 
To obtain bone marrow mesenchymal stem cells, bone 
marrow aspirates were obtained from the posterior 
iliac crests of 12 adult donors, with the approval from 
the IRB (2017-0308-001) of the Yonsei University 
College of Medicine. Cell culture was performed, as 
described previously.[8] ATDC5 mouse chondrocyte 
cells were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). ATDC5 cells were maintained in 
high-glucose DMEM (DMEM-HG; Invitrogen) 
supplemented with 10% FBS and 1% antibiotic–
antimycotic solution at 37°C and 5% CO2. 
AAV vector preparation and in vitro 
transduction 
All AAV serotypes (AAV1-9, 6.2, rh8, rh10, rh39, 
and rh43) were produced from the Viral Vector Core 
at University of Massachusetts Medical School. AAV 
vectors use self-complementing and the chicken 
beta-actin promoter. AAV production in this study 
involved transient transfection of HEK293 cells, 
purification by CsCl sedimentation, and titration by 
droplet digital PCR (ddPCR) on a QX200 ddPCR 
system (Bio-Rad) using the Egfp prime/probe set, as 
previously described.[9, 10] Human normal or OA 
chondrocytes, ATDC5 cells, and mesenchymal stem 
cells (MSCs) were seeded at a density of 1 × 104 cells 
per well in 24-well plates, and 24 h later, the cells were 
incubated with AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 6.2, rh8, rh10, 
rh39, or rh43 vectors packaging the green fluorescence 
protein (GFP) reporter transgene at 6000 MOI (1 X 
109/mL genome copies [GC]). After 48 h, GFP 
fluorescence was monitored using a fluorescence 
microscope to determine the efficiency of AAV 
transduction. Dose-response experiments were not 
conducted in the current study because the 
appropriate MOI for the AAVs was already 
established in a previous study.[9] 





Cells transduced with individual AAV serotypes 
were lysed using PRO-PREPTM Protein Extraction 
Solution (iNtRON Biotechnology, Seongnam, South 
Korea). Protein concentrations were determined using 
the Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). Protein samples (30 μg) were 
resolved by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE; Sigma-Aldrich) on a 10% gel. The 
resolved proteins were transferred onto membranes 
and blocked with 5% skim milk (BD, Sparks, MD, 
USA) for 1 h at room temperature. The membranes 
were probed for ~12 h using anti-GFP antibodies 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Membranes were further probed with antibodies 
against HSP90 (Santa Cruz Biotechnology), which 
served as a loading control. 
Animal experiments and in vivo transduction 
of AAV 
All animal experiments were approved by the 
Institutional Animal Care and Use Committee 
(IACUC) protocol of the Yonsei University College of 
Medicine (approval number: IACUC-2016-0099). 1 x 
1010 GC (10 μL) of each AAV serotype was injected 
intra-articularly to confirm the transduction 
efficiencies in the cartilage tissue of mice. Mice were 
fed an alfalfa-free chow diet to minimize GFP 
fluorescence following analyses. Two weeks later, the 
mice were euthanized, and the joints were collected 
for histological assessment (n = at least 6 per group). 
To confirm whether individual AAVs were 
transduced into intra-articular tissues, the collected 
samples were visualized using an animal optical 
imaging system (IVIS, Caliper Life Sciences, MA, 
USA). Scanning was performed under anesthesia at 
wavelengths of 744 and 805 nm. The fluorescence 
intensity in the histological samples from each mouse 
was calculated from the fluorescence signal 
(p/s/cm2) using Living Image software version 2.50 
(Xenogen). To ensure reproducibility, all tests were 
performed in at least three mice. 
Histology and immunohistochemistry 
Collected mouse joint tissues were fixed for 7 
days in 10% formalin at room temperature. For 
human samples, cartilage explants were obtained 
from the articular cartilage of patients (three females; 
aged 60~70) undergoing total knee arthroplasty. 
Sample collection was performed with patient consent 
after obtaining approval from the IRB (2019-1374-002) 
of the Yonsei University College of Medicine. The 
cartilage tissues were immersed in PBS at the surgical 
operating room and transferred immediately to 
DMEM/high glucose medium containing 10% FBS. 
Cartilage explants were punched into full-thickness 
cylindrical explants with a diameter of 5 mm and a 
length of 1 mm using a stainless-steel punch (Miltex 
Instruments, PA, USA). The prepared cartilage 
explants were incubated in DMEM/high glucose 
medium containing 10% FBS and treated immediately 
with each AAV at a concentration of 1 X 109 GC/mL. 
The cultures were maintained for 72 hours and then 
fixed with 10% formalin at room temperature. After 
fixation, the formalin-fixed specimens were 
embedded in paraffin. The paraffin-embedded 
sections were deparaffinized, rehydrated, and washed 
with PBS, and the tissue sections were used to 
evaluate the transduction efficiencies of individual 
AAV serotypes in mouse cartilage tissues. The 
prepared tissue samples were sliced to a thickness of 4 
μm and probed with the anti-GFP (Santa Cruz 
Biotechnology) antibody to detect GFP levels. To 
visualize GFP expression in the anti-GFP-antibody‒
probed tissues, the samples were stained with 
aminoethyl carbazole (AEC; Abcam, Cambridge, UK). 
The stained tissues were observed using a VS120 
virtual microscope (Olympus, Tokyo, Japan), and 
images of the sections were analyzed using the 
OlyVIA 2.5 program (Olympus). 
Statistical analyses 
All experiments were performed in triplicate 
using samples from at least three donors. Data are 
depicted as the mean ± standard deviation. 
Results 
AAV serotypes show different transduction 
efficiencies in chondrocytes and mesenchymal 
stem cells 
We first compared the transduction efficiency of 
AAV serotypes with different capsid sequences. 
Normal human chondrocytes were obtained from an 
intact part of cartilage explants from patients who had 
undergone surgery, and human OA chondrocytes 
were obtained from damaged regions of cartilage 
explants from patients who had undergone surgery. 
The cells were transduced with individual AAV 
serotypes and observed under a fluorescence 
microscope after 48 h. To further determine the 
transduction efficiency of individual serotypes, the 
expression of green fluorescence protein (GFP) (AAV 
vectors were GFP tagged) was determined by western 
blotting. GFP expression was detected in both normal 
and OA chondrocytes transduced with AAV2, 5, 6, 
and 6.2 serotypes (Figure 1A, C). Likewise, GFP 
expression was only detected in AAV2-, 5-, 6-, and 6.2 
serotype-transduced cells (Figure 1B, D). However, in 
human bone marrow-derived MSCs, most of the AAV 




serotypes were transduced except for AAV6 and rh43 
(Figure 1E, F). These results indicate that AAV 
serotypes are cell-type‒specific. Therefore, we 
propose that AAV2, 5, 6, and 6.2 are suitable serotypes 
for human chondrocyte-based in vitro culture systems. 
Additionally, we tested the transduction efficiency of 
AAV serotypes in the mouse chondrocyte cell line, 
ATDC5. We found that GFP fluorescence and 
expression were strongly detected in AAV5- and 
6.2-transduced ATDC5 cells, whereas the fluorescence 
and expression of GFP were weakly detected in 
AAV2-, 6-, 7-, rh10-, rh39-, and rh43-transduced cells 
(Figure S1A, B), indicating that AAV serotypes may 
also be species-type‒specific. 
Tissue-specific transduction by each AAV 
serotype 
Next, we injected each AVV serotype into the 
knee joints of mice to determine the corresponding 
transduction efficiencies, and mice were fed 
alfalfa-free chow to minimize background 
fluorescence. Each AAV serotype was injected 
intra-articularly, and then the mice were euthanized 
for further experiments after 2 weeks (Figure 2A). 
Figure 2B shows immunohistochemistry data for GFP 
expression within cartilage tissues. In the group 
injected with most AAV serotypes except for AAV1 
and AAV9, GFP was detected in the superficial zone 
of cartilage tissues of the mouse knee (Figure 2B). In 
particular, AAV2 and AAV6.2 showed greater 
transduction efficacy on chondrocytes residing within 
hard cartilage tissues, compared to other AAV 
serotypes. Our data from in vitro cell culture models 
also showed that AAV2 and AAV6.2 had great 
transduction efficiency in human chondrocytes and 
MSCs, suggesting that AAV2 and AAV6.2 are more 
specific for chondrocytes under both in vitro and in 
vivo environments. Altogether, these results 
demonstrated that AAV2 and AAV6.2 may be the best 
candidate vectors that can efficiently deliver 
therapeutic genes to chondrocytes. The introduction 
of therapeutic genes into the synovial membrane of 
the joint could a strategy for the treatment of OA[11] 
Figure 3C shows immunohistochemistry results for 
GFP expression within the synovia in mouse knee 
joints. While AAV6, AAV6.2, AAV rh10, and AAV 
rh43 showed some transduction efficacy, AAV2 
exhibited greater transduction efficiency than the 
others in the synovial membrane of the mouse knee 
joints (Figure 2C). 
 
 
Figure 1. Transduction efficiency of individual AAV serotypes within different cell culture models: (A) Representative GFP fluorescence images in human normal 
chondrocytes 2 days after transduction of individual AAV vectors. (Scale bar = 100 µm). (B) Western blot analysis of GFP expression 48 h after AAV transduction into normal 
human chondrocytes. (C) Representative GFP fluorescence images in human OA chondrocytes 2 days after transduction with individual AAV vectors. (Scale bar = 100 µm). (D) 
Western blot analysis of GFP expression 48 h after AAV transduction into human OA chondrocytes. (E) Representative GFP fluorescence images in human bone marrow MSCs 
2 days after AAV transduction. (Scale bar = 100 µm). (F) Western blot analysis of GFP expression 48 h after AAV transduction into human bone marrow MSCs. NV, no vector; 
AAV, adeno-associated virus; rh, rhesus; OA, osteoarthritis; GFP, green fluorescence protein; HSP, heat shock protein 90; MSC, mesenchymal stem cells. 





Figure 2. Transduction efficiency of individual AAV serotypes in mouse cartilage tissue: (A) Schematic of animal experiments performed in this study. Mice were fed 
an alfalfa-free chow diet to minimize the background fluorescence. Individual AAV serotypes were injected at a dose of 1 x 10 GC/10 μL. (B) Representative images of GFP (red) 
immunostaining in joint cartilage sections obtained from the knees of mice injected with individual AAV serotypes. (Scale bar = 50 µm). Quantification of GFP-positive cells in 
individual AAV serotype-infected joint sections. (C) Representative images of GFP (red) immunostaining in synovial membrane sections obtained from the knees of mice injected 
with individual AAV serotypes (Scale bar = 20 µm). Quantification of GFP-positive cells in individual AAV serotype-infected synovium sections. Data are expressed as a mean ± 
SD. GC, genome copies. 





Figure 3. Transduction efficiency of individual AAV serotypes in human cartilage explants: (A) Representative images showing GFP expression (red) in human 
cartilage explants transduced with individual AAV serotypes. (Scale bar = 50 µm). Quantification of GFP-positive cells in individual AAV serotype-infected cartilage explant 
sections. Data are expressed as the mean ± SD. (B) Schematic of the cellular and tissue specificity of individual AAV serotypes tested in this study. In this study, AAV5 and AAV6.2 
are effective in both cell and animal models. 
 
To extrapolate our experimental results to 
humans, human cartilage explants were obtained 
from patients undergoing surgical procedures. AAV 
transduction experiment with human articular 
cartilage tissue was done under the in vitro 
environment with explants. The human cartilage 
explants were cultured in chondrocyte culture 
medium containing individual AAV serotypes for 3 
days, and then frozen sections were used for 
immunohistochemistry. We confirmed that GFP 
expression was detected in the AAV2-, AAV4-, 
AAV5-, AAV6.2-, AAV rh39-, and AAV rh43-treated 
groups. In particular, the AAV2- and AAV6.2-treated 
groups display strong GFP expression, similar to the 
results in mice experiments (Figure 3A). These results 
indicated that AAV2 and AAV6.2 may be suitable for 




in vitro and in vivo studies, as well as for applications 
in human OA patients. 
Discussion 
Gene therapy is a promising treatment option for 
musculoskeletal diseases.[1, 12, 13] Due to their 
versatility, non-pathogenic properties, high gene 
delivery efficiency, and long-term persistence, AAVs 
are anticipated to be used extensively in the treatment 
of musculoskeletal diseases,[14, 15] indicating their 
high clinical value. Several studies have confirmed 
that AAVs can deliver genes to the articular joint of 
mice, and some studies have attempted to compare 
different serotypes of AAV to evaluate their 
transduction efficiencies in articular tissues.[16-18] As 
articular cartilage has a specialized architecture and 
limited regeneration capacity, the delivery of genes 
into articular chondrocytes is challenging. One way of 
overcoming this difficulty is to choose the most 
efficient vector for therapeutic gene delivery. In this 
study, we showed that AAV2 and AAV6.2 could 
effectively deliver therapeutic genes into human joint 
tissues. Others have reported that AAV2 has the 
highest transduction efficiency in the cartilage of knee 
joints [19], it has been used in clinical trials in patients 
with inflammatory arthritis.[20] Collectively, these 
studies support the current data that AAV2 is one of 
the most efficient vector systems with which to 
transfer therapeutic genes into chondrocytes of 
human joint cartilage. Our results also showed that 
AAV6.2, an AAV6F129L point mutant, may be very 
effective in transducing therapeutic genes into human 
joint tissue (Figure 3). AAV6.2 was found to be 2-fold 
more efficient than AAV6 in transducing mouse 
airway epithelium.[21] Another study showed that a 
triple AAV6 mutant, termed AAV6.2FF, was 10-fold 
more efficient than AAV6 for transgene expression in 
the lung.[22] Our results also showed that AAV6.2 
was approximately four times more efficient than 
AAV6 in the transduction of human cartilage explants 
when the experiments were conducted under the in 
vitro conditions (Figure 3). This is the first study to 
report the high transduction efficiency of AAV6.2 for 
transgene delivery into human chondrocytes as well 
as cartilage tissue. Therefore, we propose that AAV2 
and AAV6.2 are viable options for OA-related studies 
as well as future clinical approaches for human 
application because of their cellular and tissue 
specificity. 
Despite the many ideal results of AAV delivery 
systems into joint tissues, there are several 
considerations associated with the clinical setting. 
Different tissues, such as the synovium, in the joint 
cavity could be exposed to AAV injection. To solve 
this problem, one alternative is to incorporate a 
peptide into the AAV vector to achieve tissue 
specificity. Indeed, many researchers have tried to 
insert tissue-specific peptides to increase the 
transduction efficiency and tissue specificity for 
successful AAV-based therapies.[9, 23] We are also 
trying to develop the AAV2 and AAV6.2 vectors with 
chondrocyte-binding peptides to enhance the tissue 
specificity and improve the efficiency of AAV-based 
gene therapy. These attempts will help in applying 
AAV-based gene therapy for OA in the future. The 
current study is meaningful in that AAVs with high 
transduction efficiencies for transgene delivery in 
joint tissue were compared and determined among 
various AAV serotypes. 
Conclusion 
 In conclusion, the current study suggests that 
the use of AAV2 and AAV6.2 vectors may confer the 
best transduction efficacy in human articular cartilage 
tissue, compared to other commonly used AAV 
vector serotypes. The information provided herein 
support the selection of clinically suitable AAV 
serotypes in clinical trials of OA patients. Overall, we 
propose that intra-articular delivery of AAV2 or 
AAV6.2 vectors inserted with an appropriate 
therapeutic gene may be a promising therapeutic 
approach for preventing OA progression.  
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